Verve Therapeutics
About Us
Why Cardiovascular Disease
Our Approach
Our Pipeline
Culture & Careers
Investors
Overview
News & Events
Stock Information
Corporate Governance
Financials & Filings
IR Resources
Genome Editing: The Recent History and Perspective in Cardiovascular Diseases
Post navigation
Previous Post
Previous
In Vivo Base Editing of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) as a Therapeutic Alternative to Genome Editing
Next Post
Next
Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations
Home
About Us
Why Cardiovascular Disease
Our Approach
Our Pipeline
Culture & Careers
Investors
►
◄ Back
Overview
News & Events
Stock Information
Corporate Governance
Financials & Filings
IR Resources
Contact Us